the primary incentive to do R&D has not been the product patent regime in India after TRIPS but the product patent regime in developed countries to which TRIPS has made no difference. While R&D activities have diversified, they are yet to prove their competence in innovating new products. What Indian companies have really demonstrated is the ability to develop generics for the regulated (and other) markets – an ability which they acquired and improved during the pre-TRIPS period